PMID- 26893648
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 11
IP  - 2
DP  - 2016 Feb
TI  - Protein kinase C-beta inhibitor treatment attenuates hepatic ischemia and 
      reperfusion injury in diabetic rats.
PG  - 565-570
AB  - Hepatic ischemia and reperfusion (I/R) injury plays an active role in hepatic 
      resection and transplantation. While the effects of protein kinase C (PKC)-betaII 
      activation and the role of PKC-beta inhibitors are well understood in myocardial I/R 
      in diabetes, they remain unclear in liver I/R. The aim of this study was to 
      explore the effect of PKC-beta inhibition and the potential mechanism by which PKC-beta 
      inhibitor treatment protects against hepatic I/R injury in diabetic rats. 
      Diabetic rats were established and randomized into two groups. These were an 
      untreated group (n=10), which did not receive any treatment, and a treatment 
      group (n=10), orally treated with ruboxistaurin at a dose of 5 mg/kg/day for 2 
      weeks. The rats from the two groups were subjected to hepatic I/R. Aspartate 
      transaminase (AST) and lactate dehydrogenase (LDH) levels were measured by 
      enzymatic methods at 1, 3 and 5 h after I/R. Tumor necrosis factor-alpha (TNF-alpha) and 
      intercellular adhesion molecule 1 (ICAM-1) were examined by enzyme-linked 
      immunosorbent assay at the same time-points. Nuclear factor-kappaB (NF-kappaB) p65 
      expression was analyzed by immunofluorescence and western blotting. Apoptosis of 
      hepatic cells was examined by the western blot analysis of caspase 3 expression 
      and by DNA ladder analysis. Pathological changes were examined using light and 
      electron microscopy. Serum AST and LDH levels in the PKC-beta inhibitor treatment 
      group were diminished compared with those in the untreated group (P<0.01). Serum 
      TNF-alpha and ICAM-1 (P<0.01) levels were also decreased at different time-points in 
      the PKC-beta inhibitor treatment group. The relative expression of NF-kappaB p65 and 
      caspase 3 in the hepatic tissue was weakened in the PKC-beta inhibitor treatment 
      group compared with that in the untreated group (P<0.01). Pathological changes in 
      hepatic tissue were attenuated by the PKC-beta inhibitor. In conclusion, PKC-beta 
      inhibitor treatment protected against liver I/R injury in diabetic rats. The 
      mechanisms probably involved the attenuation of microvascular injury, reduced 
      transport of injury-associated factors and diminishment of the activation of 
      NF-kappaB p65.
FAU - Meng, Guang-Xing
AU  - Meng GX
AD  - Department of Hepatobiliary Surgery, Tianjin Hepatobiliary Research Institute, 
      Tianjin Third Central Hospital, Tianjin 300170, P.R. China.
FAU - Yuan, Qiang
AU  - Yuan Q
AD  - Department of Hepatobiliary Surgery, Tianjin Hepatobiliary Research Institute, 
      Tianjin Third Central Hospital, Tianjin 300170, P.R. China.
FAU - Wei, Li-Ping
AU  - Wei LP
AD  - Department of Cardiology, Tianjin Union Medicine Center, Tianjin 300121, P.R. 
      China.
FAU - Meng, Hua
AU  - Meng H
AD  - Department of Gastrointestinal Surgery, Beijing Friendship Hospital, Capital 
      Medical University, Beijing 100050, P.R. China.
FAU - Wang, Yi-Jun
AU  - Wang YJ
AD  - Department of Hepatobiliary Surgery, Tianjin Hepatobiliary Research Institute, 
      Tianjin Third Central Hospital, Tianjin 300170, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20151209
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC4734052
OTO - NOTNLM
OT  - diabetes
OT  - hepatic ischemia/reperfusion injury
OT  - protein kinase C-beta inhibitor
EDAT- 2016/02/20 06:00
MHDA- 2016/02/20 06:01
PMCR- 2015/12/09
CRDT- 2016/02/20 06:00
PHST- 2014/04/24 00:00 [received]
PHST- 2014/12/12 00:00 [accepted]
PHST- 2016/02/20 06:00 [entrez]
PHST- 2016/02/20 06:00 [pubmed]
PHST- 2016/02/20 06:01 [medline]
PHST- 2015/12/09 00:00 [pmc-release]
AID - ETM-0-0-2927 [pii]
AID - 10.3892/etm.2015.2927 [doi]
PST - ppublish
SO  - Exp Ther Med. 2016 Feb;11(2):565-570. doi: 10.3892/etm.2015.2927. Epub 2015 Dec 
      9.